Quick Answer
ARS Pharmaceuticals, Inc. reported R&D Expense of $13.18 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $13.18M | -32.7% |
| 2024 | $19.58M | -3.4% |
| 2023 | $20.27M | +10.3% |
| 2022 | $18.38M | -9.4% |
| 2021 | $20.27M | -17.5% |
| 2020 | $24.58M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.75M | -37.8% | -31.8% |
| June 30, 2025 | $4.04M | -41.5% | +36.7% |
| March 31, 2025 | $2.95M | -43.6% | -33.3% |
| September 30, 2024 | $4.42M | +47.3% | -35.9% |
| June 30, 2024 | $6.90M | -5.6% | +31.8% |
| March 31, 2024 | $5.23M | -20.1% | +74.4% |
| September 30, 2023 | $3.00M | -22.9% | -58.9% |
| June 30, 2023 | $7.31M | +68.0% | +11.5% |
- ARS Pharmaceuticals, Inc. showed a decrease of -32.7% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, ARS Pharmaceuticals, Inc.’s r&d expense has declined by 46.4% (from $24.58 million to $13.18 million).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: